You have free access to this content

Cancer

Cover image for Vol. 117 Issue 12

15 June 2011

Volume 117, Issue 12

Pages 2583–2826

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Communications
    6. Correspondence
    7. Errata
    1. You have free access to this content
    2. You have free access to this content
      New insights into telomeres, stress, and cancer risk (page 2585)

      Carrie Printz

      Version of Record online: 8 JUN 2011 | DOI: 10.1002/cncr.26259

  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Communications
    6. Correspondence
    7. Errata
    1. You have free access to this content
      Progression-free survival as a surrogate marker of overall survival : Is it the good question? (pages 2586–2587)

      Bernard Escudier

      Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25955

      The use of progression-free survival as a surrogate marker of efficacy in cancer treatment has been the subject of much discussion in recent years. However, it should not be considered a surrogate marker for overall survival.

    2. You have free access to this content
      Measuring success in ovarian cancer risk reducing strategies (pages 2588–2589)

      Annekathryn Goodman

      Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25946

      Success in ovarian cancer risk-reducing strategies is based in outcome data and on patient satisfaction. Despite increased estrogen deficiency symptoms, satisfaction rates were higher with risk-reducing bilateral salpingo-oophorectomy. Reduced satisfaction was due to uncertainty in decision making.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Communications
    6. Correspondence
    7. Errata
    1. Disease Site

      Breast Disease
      You have free access to this content
      Disparities in the application of adjuvant radiotherapy after breast-conserving surgery for early stage breast cancer : Impact on overall survival (pages 2590–2598)

      Anthony E. Dragun, Bin Huang, Thomas C. Tucker and William J. Spanos

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25821

      • original image
      • original image

      Adjuvant radiotherapy after breast-conserving surgery is disproportionately omitted in elderly, rural, racial minority, and uninsured populations, and there has been little improvement in this measure during the last decade. This report is one of the largest studies to date to identify an independent association of lack of radiotherapy with an increased hazard ratio for death.

    2. You have free access to this content
      A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes (pages 2599–2607)

      Sheldon Feldman, Savitri Krishnamurthy, William Gillanders, Mark Gittleman, Peter D. Beitsch, Peter R. Young, Christian J. Streck, Pat W. Whitworth, Edward A. Levine, Susan Boolbol, Linda K. Han, Robert Hermann, Dave S. B. Hoon, Armando E. Giuliano, Funda Meric-Bernstam and for the US One Step Nucleic Acid Amplification Clinical Study Group

      Version of Record online: 11 JAN 2011 | DOI: 10.1002/cncr.25822

      In this prospective, multicenter study, the authors examined the performance of an automated molecular assay for the objective and standardized real-time detection of metastatic carcinoma in sentinel lymph nodes. The assay demonstrated performance that was comparable to that of standard postoperative histopathology and better than that of intraoperative imprint cytology.

    3. Gastrointestinal Disease
      You have free access to this content
      Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer (pages 2608–2619)

      Jong-Tae Kim, Eun Young Song, Kyung-Sook Chung, Min Ah Kang, Jae Wha Kim, Sang Jick Kim, Young Il Yeom, Joo Heon Kim, Kyo Hyun Kim and Hee Gu Lee

      Version of Record online: 23 DEC 2010 | DOI: 10.1002/cncr.25841

      • original image
      • original image
      • original image
      • original image

      In this study, kallikrein-related peptidase 6 (KLK6) was up-regulated significantly in colon cancer tissues and in sera from patients with colon cancer. In addition, KLK6 was closely associated with a poor prognosis, suggesting that KLK6 may be used as a potential biomarker and therapeutic target for colon cancer.

    4. You have free access to this content
      A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : Cancer and Leukemia Group B (CALGB) 80003 (pages 2620–2628)

      Harvey J. Mamon, Donna Niedzwiecki, Donna Hollis, Benjamin R. Tan, Robert J. Mayer, Joel E. Tepper, Richard M. Goldberg, A. William Blackstock, Charles S. Fuchs and for the Cancer and Leukemia Group B

      Version of Record online: 23 DEC 2010 | DOI: 10.1002/cncr.25742

      • original image
      • original image
      • original image
      • original image

      This phase 2 cooperative group trial combined 2 types of radiosensitizing chemotherapy, 5-fluorouracil and gemcitabine, with external beam radiation therapy in the treatment of patients with locally advanced pancreatic cancer. The regimen was well tolerated, with a median time to progression of 10 months and a median overall survival of 12.2 months.

    5. Genitourinary Disease
      You have free access to this content
      Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence (pages 2629–2636)

      Tim J. Kruser, David F. Jarrard, Andrew K. Graf, Sean P. Hedican, David R. Paolone, John D. Wegenke, Glenn Liu, Heather M. Geye and Mark A. Ritter

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25824

      • original image
      • original image

      The authors report on toxicity and efficacy of an expedited, hypofractionated course of radiotherapy for patients demonstrating biochemical recurrence after radical prostatectomy (RP). The results presented suggest this may represent a safe, effective, and resource-efficient treatment for the estimated 20,000 to 35,000 men experiencing biochemical recurrence after RP each year in the United States.

    6. You have free access to this content
      Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy (pages 2637–2642)

      Daniel Y. C. Heng, Wanling Xie, Georg A. Bjarnason, Ulka Vaishampayan, Min-Han Tan, Jennifer Knox, Frede Donskov, Lori Wood, Christian Kollmannsberger, Brian I. Rini and Toni K. Choueiri

      Version of Record online: 18 NOV 2010 | DOI: 10.1002/cncr.25750

      • original image

      Progression at 3 months and 6 months was an independent predictor of overall survival in patients with metastatic renal cell carcinoma. In addition, there was a statistically significant, dependent correlation between progression-free survival and overall survival.

    7. Gynecologic Oncology
      You have free access to this content
      Assessing gynecologic and breast cancer survivors' sexual health care needs (pages 2643–2651)

      Emily K. Hill, Stacey Sandbo, Emily Abramsohn, Jennifer Makelarski, Kristen Wroblewski, Emily R. Wenrich, Stacy McCoy, Sarah M. Temkin, S. Diane Yamada and Stacy T. Lindau

      Version of Record online: 23 DEC 2010 | DOI: 10.1002/cncr.25832

      • original image
      • original image
      • original image

      Greater than 40% of gynecologic and breast cancer survivors expressed interest in receiving medical care to address sexual issues, but few had ever sought such care. Younger women and those who were not actively undergoing treatment had significantly more interest in and willingness to seek care.

    8. You have free access to this content
      Correlation of LAPTM4B polymorphisms with cervical carcinoma (pages 2652–2658)

      Fanling Meng, Hongtao Song, Chang Luo, Mingzhu Yin, Ye Xu, Haixia Liu, Rouli Zhou and Ge Lou

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25833

      • original image
      • original image

      This study investigated the association between different LAPTM4B alleles and the risk of cervical carcinoma. Our findings indicate that the LAPTM4B*2 allele might play an important role in genetic susceptibility to cervical cancer in the Chinese population.

    9. You have free access to this content
      Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma (pages 2659–2667)

      Shannon N. Westin, Charlotte C. Sun, Karen H. Lu, Kathleen M. Schmeler, Pamela T. Soliman, Robin A. Lacour, Kristin G. Johnson, Molly S. Daniels, Banu K. Arun, Susan K. Peterson and Diane C. Bodurka

      Version of Record online: 29 DEC 2010 | DOI: 10.1002/cncr.25820

      Ovarian cancer risk reduction options for women who are at high risk for breast and ovarian cancer include periodic screening and risk-reducing salpingo-oophorectomy. In the current study, the authors observed that women who chose periodic screening had lower levels of satisfaction with their chosen risk-reduction strategy compared with women who chose risk-reducing salpingo-oophorectomy.

    10. Head and Neck Disease
      You have free access to this content
      Oncologic outcomes of open conservation laryngectomy for radiorecurrent laryngeal carcinoma : A systematic review and meta-analysis of english-language literature (pages 2668–2676)

      Vinidh Paleri, Ligy Thomas, Natesh Basavaiah, Mike Drinnan, Hisham Mehanna and Terry Jones

      Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25831

      • original image
      • original image
      • original image
      • original image
      • original image

      Open conservation (partial) laryngectomies are oncologically sound procedures in the salvage setting for selected patients with radiorecurrent cancers. In the current study, high local control rates (87%) at 24 months were associated with high larynx preservation rates (85%).

    11. You have free access to this content
      Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma (pages 2677–2689)

      Elizabeth Van Tubergen, Robert Vander Broek, Julia Lee, Gregory Wolf, Thomas Carey, Carol Bradford, Mark Prince, Keith L. Kirkwood and Nisha J. D'Silva

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25859

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Tristetraprolin (TTP), a protein that decreases the stability of messenger RNA (mRNA) of cytokines and proinflammatory factors, is reduced in patients with head and neck squamous cell carcinoma with a corresponding increase in interleukin-6 (IL-6), vascular endothelial growth factor, and cyclooxygenase-2 secretion. One of these tumor-derived cytokines, IL-6, is prognostic for poor disease-specific survival, tumor recurrence, second primary lesions, and poor overall survival.

    12. Hematologic Malignancies
      You have free access to this content
      Activity of azacitidine in chronic myelomonocytic leukemia (pages 2690–2696)

      Rubens Costa, Haifaa Abdulhaq, Bushra Haq, Richard K. Shadduck, Joan Latsko, Mazen Zenati, Folefac D. Atem, James M. Rossetti, Entezam A. Sahovic and John Lister

      Version of Record online: 23 DEC 2010 | DOI: 10.1002/cncr.25759

      • original image
      • original image
      • original image
      • original image

      Azacitidine is active in the treatment of CMML. The therapy-associated toxicity is acceptable.

    13. You have free access to this content
      Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes (pages 2697–2702)

      Lewis R. Silverman, Pierre Fenaux, Ghulam J. Mufti, Valeria Santini, Eva Hellström-Lindberg, Norbert Gattermann, Guillermo Sanz, Alan F. List, Steven D. Gore and John F. Seymour

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25774

      • original image
      • original image

      Continued azacitidine therapy is associated with a quantitative increase in response to a higher response category. Therefore, continued azacitidine therapy may enhance clinical benefit in patients with higher-risk myelodysplastic syndromes.

    14. Lung Disease
      You have free access to this content
      Modeling the mortality reduction due to computed tomography screening for lung cancer (pages 2703–2708)

      Millennia Foy, Rowena Yip, Xing Chen, Marek Kimmel, Olga Y. Gorlova and Claudia I. Henschke

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25847

      • original image
      • original image
      • original image
      • original image
      • original image

      There were 64 observed lung cancer deaths in the computed tomography (CT) screening cohort (n = 7995) over the 10 years of follow-up, whereas the validated model predicted 117.7 deaths (95% confidence interval, 98 deaths-139 deaths) in the absence of screening, indicating a mortality reduction of 45.6% (P < .001). These results indicate that CT screening along with early stage treatment can reduce lung cancer-specific mortality.

      Corrected by:

      Erratum: Correction

      Vol. 117, Issue 14, 3286, Version of Record online: 26 APR 2011

    15. You have free access to this content
      A novel KIF5B-ALK variant in nonsmall cell lung cancer (pages 2709–2718)

      Daisy Wing-Sze Wong, Elaine Lai-Han Leung, Sunny Kit-Man Wong, Vicky Pui-Chi Tin, Alan Dart-Loon Sihoe, Lik-Cheung Cheng, Joseph Siu-Kie Au, Lap-Ping Chung and Maria Pik Wong

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25843

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The kinesin family member 5B-anaplastic lymphoma kinase (KIF5B-ALK) fusion gene with a novel breakpoint was identified in a Chinese patient with primary lung adenocarcinoma. The discovery of the novel KIF5B-ALK variant further consolidated the role of aberrant ALK signaling in lung carcinogenesis.

    16. Melanoma
      You have free access to this content
      Prognostic significance of RUNX3 expression in human melanoma (pages 2719–2727)

      Zhizhong Zhang, Guangdi Chen, Yabin Cheng, Magdalena Martinka and Gang Li

      Version of Record online: 23 DEC 2010 | DOI: 10.1002/cncr.25838

      • original image
      • original image
      • original image
      • original image

      Loss of RUNX3 expression was correlated with a worse 5-year survival of melanoma patients and may serve as a promising prognostic marker for melanoma.

    17. Sarcoma
      You have free access to this content
      Soft tissue sarcomas of the popliteal fossa : A single-institution retrospective review (pages 2728–2734)

      Winston W. Huh, B. Ashleigh Guadagnolo, Mark F. Munsell, Shreyaskumar Patel and Valerae O. Lewis

      Version of Record online: 29 DEC 2010 | DOI: 10.1002/cncr.25736

      • original image
      • original image
      • original image

      The popliteal fossa is a rare site for primary tumor presentation of soft tissue sarcoma and represents a challenge for local tumor treatment. Radiation therapy may play an important role in the treatment of local tumors, and neurovascular involvement may not represent a poor prognostic indicator.

    18. Discipline

      Complementary Medicine
      You have free access to this content
      Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-cell leukemia (pages 2735–2746)

      Ning Ding, Uki Yamashita, Hidetada Matsuoka, Tsutomu Sugiura, Junichi Tsukada, Junko Noguchi and Yasuhiro Yoshida

      Version of Record online: 23 DEC 2010 | DOI: 10.1002/cncr.25711

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Cucurbitacin D inhibits proliferation and induces apoptosis through NF-κB inactivation in 6 kinds of T-cell leukemia cell lines. Cucurbitacin D suppresses proteasome activities during the process of apoptosis.

    19. Disparities Research
      You have free access to this content
      Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations (pages 2747–2753)

      Kathryn C. Amirikia, Paul Mills, Jason Bush and Lisa A Newman

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25862

      • original image
      • original image
      • original image
      • original image

      The California Cancer Registry revealed higher population-based incidence rates of early onset, advanced-stage, and triple-negative breast cancer for African-American women compared with white American women. These findings suggested that mammographic screening will be particularly important for young African-American women.

    20. You have free access to this content
      Patient navigation for American Indians undergoing cancer treatment : Utilization and impact on care delivery in a regional healthcare center (pages 2754–2761)

      B. Ashleigh Guadagnolo, Amy Boylan, Michele Sargent, David Koop, Deb Brunette, Shalini Kanekar, Vanessa Shortbull, Kevin Molloy and Daniel G. Petereit

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25823

      • original image

      Patient navigation was associated with fewer radiation therapy treatment interruptions and relatively high rates of clinical trial enrollment among American Indian cancer patients presenting to this regional health care center, which services a medically underserved area.

    21. You have free access to this content
      Studying cancer in minorities : A look at the numbers (pages 2762–2769)

      Sara H. Olson, Tracy M. Layne, Jennifer A. Simon, Emmy Ludwig, Eileen O'Reilly, Peter J. Allen and Robert C. Kurtz

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25871

      • original image
      • original image

      This article shows that the number of patients in SEER registries with cancers that have higher incidence in minorities is quite small for all but the most common cancers. In part, this is because of sharp declines in the size of minority populations in older age groups likely to be affected with cancer.

    22. Pediatric Oncology
      You have free access to this content
      Frontline treatment of localized osteosarcoma without methotrexate : Results of the St. Jude Children's Research Hospital OS99 Trial (pages 2770–2778)

      Najat C. Daw, Michael D. Neel, Bhaskar N. Rao, Catherine A. Billups, Jianrong Wu, Jesse J. Jenkins, Juan Quintana, Lori Luchtman-Jones, Milena Villarroel and Victor M. Santana

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25715

      • original image
      • original image
      • original image
      • original image

      The treatment of localized, resectable osteosarcoma with carboplatin, ifosfamide, and doxorubicin produces event-free survival and survival results that are comparable to those of cisplatin-containing or high-dose methotrexate (HDMTX)-containing regimens. This regimen offers a good alternative for patients, particularly those who demonstrate intolerance of HDMTX, and for institutions that cannot provide MTX monitoring.

    23. Quality of Life
      You have free access to this content
      Symptom burden in cancer survivors 1 year after diagnosis : A Report From the American Cancer Society's Studies of Cancer Survivors (pages 2779–2790)

      Qiuling Shi, Tenbroeck G. Smith, Jared D. Michonski, Kevin D. Stein, Chiewkwei Kaw and Charles S. Cleeland

      Version of Record online: 14 APR 2011 | DOI: 10.1002/cncr.26146

      Cancer survivors are at risk for multiple persistent symptoms. This analysis of data from the American Cancer Society's Study of Cancer Survivors-I revealed that >25% of survivors have high symptom burden 1 year postdiagnosis, even after treatment termination. Associated risk factors and symptom impact on quality of life were examined.

    24. Psychosocial Oncology
      You have free access to this content
      Medical expenditures of adult cancer survivors aged <65 years in the United States (pages 2791–2800)

      Pamela Farley Short, John R. Moran and Rajeshwari Punekar

      Version of Record online: 23 DEC 2010 | DOI: 10.1002/cncr.25835

      • original image
      • original image
      • original image
      • original image

      The results from this study indicated that the increase in expenditures attributable to cancer was substantial, even for longer term survivors. Cancer increased the relative risk of high out-of-pocket expenditures.

    25. Radiation Oncology
      You have free access to this content
      Outcomes of malignant tumors of the lacrimal apparatus : The University of Texas MD Anderson Cancer Center experience (pages 2801–2810)

      Heath D. Skinner, Adam S. Garden, David I. Rosenthal, K. Kian Ang, William H. Morrison, Bita Esmaeli, Chelsea C. Pinnix and Steven J. Frank

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25813

      • original image
      • original image
      • original image
      • original image

      Outcomes after eye-sparing surgery are similar to those after orbital exenteration for tumors of the lacrimal apparatus. Postoperative radiotherapy greatly improves locoregional control of this disease.

  4. Communications

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Communications
    6. Correspondence
    7. Errata
    1. You have free access to this content
      A note from history: Landmarks in history of cancer, part 2 (pages 2811–2820)

      Steven I. Hajdu

      Version of Record online: 29 DEC 2010 | DOI: 10.1002/cncr.25825

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      This illustrated narrative lists the major advances made in diagnosis and treatment of cancer from 1500 to 1750.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Communications
    6. Correspondence
    7. Errata
    1. You have free access to this content
      Assessment of capsular melanoma cell deposits in sentinel lymph nodes (page 2821)

      Hans Peter Bertsch and Lutz Kretschmer

      Version of Record online: 24 JAN 2011 | DOI: 10.1002/cncr.25785

    2. You have free access to this content
      Reply to assessment of capsular melanoma cell deposits in sentinel lymph nodes (page 2821)

      Andre Meier, Imke Satzger, Bernward Völker, Alexander Kapp and Ralf Gutzmer

      Version of Record online: 24 JAN 2011 | DOI: 10.1002/cncr.25789

    3. You have free access to this content
      High-intensity focused ultrasound (HIFU) is not indicated for treatment of primary bone sarcomas (page 2822)

      Stefan S. Bielack, Neyssa Marina and Mark Bernstein

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25881

      Surgery is the method of choice for local treatment of osteosarcoma. Experimental approaches should not be considered “safe” unless they are proven to produce equivalent local control rates.

    4. You have free access to this content
      Reply to high-intensity focused ultrasound (HIFU) is not indicated for treatment of primary bone sarcomas (pages 2822–2823)

      Chuanxing Li, Weidong Zhang, Weijun Fan, Jinhua Huang, Fujun Zhang and Peihong Wu

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25880

    5. You have free access to this content
    6. You have free access to this content
  6. Errata

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Communications
    6. Correspondence
    7. Errata
    1. You have free access to this content
      Erratum: Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer (page 2825)

      Matthew R. Cooperberg, Andrew J. Vickers, Jeanette M. Broering, Peter R. Carroll and for the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Investigators

      Version of Record online: 24 JAN 2011 | DOI: 10.1002/cncr.25914

    2. You have free access to this content
      Erratum: Nuclear Localization of Nm23-H1 in Head and Neck Squamous Cell Carcinoma Is Associated With Radiation Resistance (page 2825)

      Haeng Ran Park, Se-Heon Kim, Sei Young Lee, Ji Min Sung, Ae Ran Park, Suki Kang, Baek Gil Kim, Yoon Pyo Choi, Yong-Bae Kim and Nam Hoon Cho

      Version of Record online: 29 DEC 2010 | DOI: 10.1002/cncr.25913

      This article corrects:
    3. You have free access to this content
      Erratum: Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases (page 2826)

      Johnny Kao, Stuart Packer, Ha Linh Vu, Myron E. Schwartz, Max W. Sung, Richard G. Stock, Yeh-Chi Lo, Delphine Huang, Shu-Hsia Chen and Jamie A. Cesaretti

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25829

      • original image
      This article corrects:

SEARCH

SEARCH BY CITATION